Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings
On track for full data read out in the first half of 2026
You might also be interested in reading CoinDesk 20 Performance Update: ICP Drops 5.6% as Index Trades Lower From Tuesday.